GCP
RDHL

GSA Capital Partners’s Redhill Biopharma RDHL Stock Holding History

GSA Capital Partners’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17
Closed -$14K – 1804
2022
Q2 		$14K Buy
+17
New +$23.3K ﹤0.01% 1326
2022
Q1 		– Sell
-218
Closed -$563K – 1759
2021
Q4 		$563K Buy
218
+113
+108% +$452K 0.07% 525
2021
Q3 		$480K Buy
105
+23
+28% +$156K 0.05% 720
2021
Q2 		$563K Buy
82
+64
+356% +$442K 0.06% 559
2021
Q1 		$133K Sell
18
-27
-60% -$226K 0.02% 974
2020
Q4 		$360K Buy
+45
New +$404K 0.06% 638

Other funds holding RDHL

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $62.3B AUM 44.64% 1-Year Est. Return

GSA Capital Partners's RDHL Position: Q3 2022 in Review

GSA Capital Partners sold out of Redhill Biopharma (RDHL) in Q3 2022, closing a stake of 17 shares — an estimated $14K sold.

GSA Capital Partners first reported a position in RDHL in Q4 2020 and held it in 6 quarters. The position peaked at $563K in Q4 2021. 40 funds tracked by Wall St. Rank hold RDHL as of Q3 2022.

  • GSA Capital Partners reported no remaining Redhill Biopharma position as of Q3 2022 after selling out during the quarter.
  • GSA Capital Partners sold 17 Redhill Biopharma shares in Q3 2022, an estimated $14K.
  • GSA Capital Partners first reported a position in Redhill Biopharma in Q4 2020 and held it in 6 quarters.
  • GSA Capital Partners's Redhill Biopharma position peaked at $563K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.